Recurr ent venous thrombosis despite 'optimal anticoagulation therapy' for antiphospholipid syndrome - Could new oral anticoagulants solve the problem?

Acta Clinica Croatica

Volumn 49, Issue 4, 2010, Pages 469-477

  Balaban, Manuela ^a   Stancic, Vladimir ^a   Rincic, Goran ^a   Ledinsky, Mario ^a,b   Grbac, Ljiljana ^c   Stancic, Nevenka ^a   Tomašic, Hrvoje ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b University Hospital Sveti Duh   (Croatia)

^c Po ega General Hospital   (Croatia)

Author keywords

Antiphospholipid syndrome complications; Antiphospholipid syndrome drug therapy; Case report; Thrombosis etiology; Thrombosis prevention and control; Warfarin therapeutic use

Indexed keywords

BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; CREATININE; D DIMER; DABIGATRAN; DALTEPARIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A;

ADULT; ANEMIA; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ATHEROSCLEROSIS; CASE REPORT; CREATININE CLEARANCE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LEG ARTERY; LEG THROMBOSIS; LOW DRUG DOSE; LUNG EMBOLISM; PATIENT MONITORING; PROTHROMBIN TIME; RECURRENT DISEASE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VALIDITY; BLOOD; DRUG ANTAGONISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; REVIEW; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBINS; FACTOR XA; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; PROTHROMBIN TIME; RECURRENCE; VENOUS THROMBOSIS; WARFARIN;

EID: 80052797627     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Harris EN, Gharavi AE, Hughes GRV. Antiphospholipid syndrome. Clin Rheum Dis 1985;11:591-609.
2. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJW. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985;19:265-75.
3. Finazzi G, Brancaccio V, Moia M, Ciavarella N, Mazzucconi MG, Schinco PC, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996;100:530-6.
4. Meroni PL, Del Papa N, Raschi E. ß2-glycoprotein I as a cofactor for anti-phospholipid antibody reactivity with endothelial cells. Lupus 1998;7(Suppl 2):44-7.
5. Salonen JT, Yla-Hertutuala S, Yamamoto R. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-7.
6. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993;81:2618-25.
7. De Groot PG, Derk sen HWM. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005;3:1854-60.
8. Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004;136:393-401.
9. Creamer D, Hunt BJ, Black MM. Widespread cutaneous necrosis occurring in association with the antiphospholipid syndrome. Br J Dermatol 2000;142:1199-203.
10. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997;127:177-85.
11. Tripodi A, Chantarangkul V, Clerici M. Laboratory control of oral anticoagulant treatment by the IN R system in patients with antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol 2001;115:672-8.
12. Rosove MH, Brewer PM C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
13. Khamashta MA, Cuadrado MJ, Mujic F. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
14. Krnic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997;157:2101-8.
15. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-8.
16. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-7.
17. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
18. Mannucci PM, Canciani MT, Mari D, Meucci P. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupuslike anticoagulant. Scand J Haematol 1979;22:423-32.
19. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996;47:533-53.
20. Galli M, Beguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Br J Haematol 1989;72:549-55.
21. Horellou MH, Aurousseau MH, Boffa MC, Conrad J, Wiesel ML, Samama M. Biological and clinical heterogeneity of lupus and lupus-like anti-coagulant in fifty-seven patients. J Med 1987;18:199-217.
22. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988;72:512-9.
23. Bick RL, Baker WF Jr. The antiphospholipid and thrombosis syndromes. Med Clin North Am 1994;78:667-84.
24. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(4 Suppl):258S-275S.
25. Linkins LA, Weitz JI. New anticoagulants. Sem Thromb Hemost 2003;29:619-31.
26. Mueck W, Eriksson BI, Bauer KA. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47:203-16.
27. Eriksson BI, Borris L, Dahl OE. Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006;4:121-8.
28. Kakkar AK, Br enner B, Da hl OE. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372(9632):31-9.
29. Lassen MR, Ageno W, Borris LC. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86.
30. Turpie A, Bauer K, Davidson B, et al. Comparison of rivaroxaban - an oral, direct factor Xa inhibitor - and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4). Paper presented at: European Federation of National Associations of Orthopaedics and Traumatology, May 29-June 1, 2008; Nice, France.
31. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
32. Eriksson BI, Dahl OE, Rosencher N. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
33. Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, and the RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009;361:1139-51.
34. Schulman S, Kearon C, Kakkar KA, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, for the RE-COVE R Study Group Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009;361:2342-52.
35. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADV ANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADV ANCE-2): a randomized doubleblind trial. Lancet 2010;6(375):807-15.